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Abstract
Introduction: One‐third of the patients with pancreatic cancer present with locally
advanced unresectable pancreatic cancer (LAPC). Our aim was to determine survival
outcomes and toxicity after FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and
oxaliplatin) followed by radiotherapy (RT) in biopsy‐proven patients with LAPC.
Methods: We analysed a cohort of biopsy‐proven patients with LAPC, who were eligible
for induction FOLFIRINOX (eight cycles) and subsequent RT (30 fractions, 60 Gy). Eligible
patients underwent a staging laparoscopy to detect occult metastasis before the
treatment. The primary outcome was overall survival (OS), and secondary outcomes
were progression‐free survival (PFS), treatment‐related toxicity, and resection rate.
Results: Forty‐four patients were diagnosed with biopsy‐proven LAPC. Twenty‐five
patients were eligible and all underwent staging laparoscopy before the treatment. In
three (12%) patients occult metastases were found. Twenty‐two patients started
induction FOLFIRINOX, 17 (77%) completed all cycles. Seventeen (77%) patients
were treated with subsequent RT, with 16 (94%) receiving the full dosage. Three
(14%) patients underwent a radical resection after the treatment. Median OS was
15.4 months (95% confidence interval [CI], 10.0‐20.7), median PFS was 11 months
(95% CI, 7.7‐14.4).
Conclusions: Median OS after FOLFIRINOX and RT was 15 months in patients with
LAPC. Toxicity remains severe, however, most patients completed all eight scheduled
cycles of FOLFIRINOX and RT.
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1 | INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer‐related deaths,
with projections to be the second leading cause of cancer‐related
deaths in 2030.1 Pancreatic cancer can be divided in three groups:
resectable pancreatic cancer (stage I or II; 15%), locally advanced
unresectable pancreatic cancer (LAPC) (stage III; 35%), and metastatic
disease (stage IV; 50%).2 Resectability of pancreatic cancer is
determined by the extent of tumor contact with the superior
mesenteric artery (SMA), coeliac artery, common hepatic artery,
superior mesenteric vein, and portal vein. There are several definitions
for resectability, which mainly differ in the extent of vascular tumor
contact on computed tomography (CT). The Dutch Pancreatic Cancer
Group has defined LAPC as venous tumor contact exceeding 270
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degrees or arterial contact exceeding 90 degrees (Table 1) without
distant metastases.3 The initial treatment for LAPC is a systemic
chemotherapy.4 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and
oxaliplatin) is the preferred treatment, based upon the results of a
randomized study showing a significant and relevant improvement in
overall survival (OS) compared with gemcitabine in patients with
metastatic disease (median OS 11.1 vs 6.8 months; P < 0.0001).5 No
randomized trials have been published on FOLFIRINOX in patients with
LAPC. However, several case series have shown favorable survival with
a median OS ranging from 10.0 to 32.7 months.6 Patients who do not
develop the metastatic disease during FOLFIRINOX may benefit from
subsequent radiotherapy (RT) for local control.4
The objective of this study was to assess survival outcomes and
toxicity of FOLFIRINOX followed by RT in patients with LAPC.
2 | METHODS
Between January 2012 and December 2014, all consecutive patients
diagnosed with biopsy‐proven LAPC who received induction
FOLFIRINOX at the Erasmus MC Cancer Institute were enrolled in
a local database. No informed consent was obtained from the
patients during this period as the standard local treatment was
induction FOLFIRINOX followed by RT. Furthermore, all patients
who had biopsy‐proven LAPC but did not receive the FOLFIRINOX
treatment in the same period were retrospectively identified by
searching the local review board meeting reports. LAPC was defined
as tumor contact with the SMA, coeliac artery, or common hepatic
artery exceeding 90 degrees, or contact with the superior mesenteric
vein or portal vein exceeding 270 degrees on CT scan, in the absence
of metastatic disease.3
Patients were eligible for FOLFIRINOX and RT if they had a
World Health Organization (WHO) performance status of 0 or 1,
and were not older than 75 years. The diagnostic workup of patients
with suspicion of LAPC consists of a CT scan of the thorax,
abdomen, and pelvis.4 Histopathological diagnosis of pancreatic
cancer was confirmed with biopsy by endoscopic ultrasound in all
patients. After confirmation of the diagnosis, a staging laparoscopy
was performed to exclude occult metastases. FOLFIRINOX treat-
ment was started within 4 weeks after staging laparoscopy in all
patients. The dose of FOLFIRINOX was according to the PRODIGE
4 trial, consisting of a 2 hour intravenous infusion of oxaliplatin
(85 mg/m2) followed by a 2 hour intravenous infusion of leucovorin
(400 mg/m2) concomitantly with a 90 minute intravenous infusion
of irinotecan (180 mg/m2), followed by a bolus (400 mg/m2) and a
46 hour continuous infusion (2400mg/m2) of fluorouracil.5 The
duration of a cycle was 2 weeks.7 Patients were scheduled for eight
cycles of FOLFIRINOX. Surveillance imaging was performed after
four and eight cycles of FOLFIRINOX with a tri‐phase abdominal CT
scan. Treatment was terminated if progression (according to
RECIST 1.1) was seen.8 Patients who had stable disease or partial
response received RT after eight cycles of FOLFIRINOX or earlier if
the FOLFIRINOX treatment was discontinued because of toxicity.
Dose reduction of 25% was applied if there were serious adverse
events related to one of the components of FOLFIRINOX.
Chemotherapy was discontinued if toxicity persisted after the
second dose reductions. Radiotherapy consisted of 2 Gy per fraction
to a total dose of 60 Gy. After RT, again a tri‐phase CT scan was
performed and patients were considered in a multidisciplinary
review board for curative‐intent resection. Adverse events were
graded using the National Cancer Institute Common Toxicity
Criteria 4.0.
OS was calculated from the start of the FOLFIRINOX treatment
to the date of death. Progression‐free survival (PFS) was calculated
from the start of FOLFIRINOX treatment to the date of progression
or death. For the patients who did not receive FOLFIRINOX, OS was
calculated from the date of histopathological confirmation of LAPC
until progression or death. Survival functions were estimated using
the Kaplan‐Meier method in the SPSS (version 21).
TABLE 1 Baseline characteristics
FOLFIRINOX
(N = 22)
No
FOLFIRINOX
(N = 19) P =
Age, median (IQR) 62 (52‐67) 62 (53‐67) 0.33
Sex 0.74
Male 6 7
Female 16 12
WHO <0.001
0‐1 22 9
2‐4 0 10
Jaundice 0.76
Yes 9 9
No 13 10
Weight loss 0.74
Yes 15 14
No 7 5
Diabetes 1.00
Yes 4 4
No 18 15
Abdominal pain 0.59
Yes 21 17
No 1 2
BMI, median (IQR) 23 (22‐25) 23 (20‐28) 0.90
Tumor origin 0.23
Head 13 12
Body 9 5
Tail 0 2
Median CA 19.9 309 (105‐912) 560 (167‐744) 0.88
Median CEA 3.5 (2.4‐12.2) 3.4 (2.2‐4.1) 0.50
Maximum tumor
size (mm),
median (IQR)
36 (30‐43) 35 (23‐40) 0.37
Locally advanced based on
Only arterial 7 9 0.35
Only venous 5 4 1.00
Both arterial and
venous
10 6 0.52
Abbreviations: BMI, body mass index; WHO, world health organization.
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3 | RESULTS
During the study period, 44 patients presented with biopsy‐proven
LAPC (Figure 1). Nineteen patients (12 [60%] female, median age
62 years) were not included due to either poor condition (WHO
performance status 2‐4 condition) (n = 10), patient preference (n = 6),
or no staging laparoscopy performed before the treatment (n = 4).
These four patients received the chemotherapy treatment in other
hospitals. A total of 25 patients were enrolled and underwent a
staging laparoscopy. In three patients (12%), occult peritoneal
metastases were identified. In total, 22 patients were scheduled for
FOLFIRINOX and RT; the remaining 19 patients received FOLFIR-
INOX in other hospitals, gemcitabine, and best supportive care.
Baseline patient and tumor characteristics were similar between the
FOLFIRINOX with RT group vs other LAPC patients, except for the
high rate of poor performance status in the latter (Table 1).
Patients who were eligible for the standard care received a
median of eight cycles of FOLFIRINOX (range 2‐9), with 4 (18%)
patients receiving less than five cycles and 18 (82%) patients
receiving at least seven cycles. The reasons for termination of the
FOLFIRINOX after less than five cycles were toxicity in 3 (14%)
patients and distant progressive disease in 1 (5%) patient. A dose
reduction was required for 8 (36%) patients, with 7 patients receiving
75%, and 1 patient 50% of the prescribed dose. No recombinant
human granulocyte colony‐stimulating factor analogs were pre-
scribed for any patient during the treatment. One patient (5%) had
a partial radiological response, 19 (83%) stable disease, and 2 (9%)
patients progressive disease after FOLFIRINOX treatment.
Five (23%) patients of the 22 did not receive RT due to
deterioration of patients’ condition (n = 3), distant progressive
disease under FOLFIRINOX (n = 2). The remaining 17 (77%) patients
received RT; 16 (94%) received the full dose of 60 Gy and only 1 (6%)
patient received 52 Gy due to the patient's condition. One (6%)
patient had a partial response, 11 (65%) patients stable disease, and
5 (29%) patients progressive disease. The progression was seen both
local and distant in three (60%) patients, and only distant in two
(40%) patients.
At last follow‐up, all 22 patients died of progressive disease. The
median PFS and OS of the group “protocolled FOLFIRINOX” (n = 22)
was 11 months (95% confidence interval [CI], 7.7‐14.4) and
15.4 months (95% CI, 10.0‐20.7), respectively (Figure 2). The actual
1‐year survival rate was 68% (95% CI, 47%‐84%), and the actual
2‐years survival rate was 14% (95% CI, 5%‐33%). The median OS
after completion of both FOLFIRINOX and RT (n = 17) was 18.7
months (95% CI, 13.4 ‐23.9). The median OS of “protocolled
FOLFIRINOX” (n = 22) from the date of histopathological confirma-
tion until the date of death was 16.3 months (95% CI, 11.4‐21.2). In
comparison, the patients who did not receive protocolled FOLFIR-
INOX and RT (n = 19) all died, and had a median OS of 6.2 months
(95% CI, 3.8–8.5) with actual 1‐year OS of 37% (95% CI, 19%‐59%)
and actual 2‐year OS of 5% (95% CI, 9%‐25%).
There were 13 (59%) grade 3 or 4 adverse events seen in
13 patients, including diarrhea (n = 4), elevated liver enzymes (n = 3),
neutropenic fever (n = 1), nausea (n = 1), mucositis (n = 1), fatigue
F IGURE 1 Flowchart of the study population [Color figure can be
viewed at wileyonlinelibrary.com]
F IGURE 2 Kaplan‐Meier curves of OS and PFS for the
patients treated with FOLFIRINOX. OS, overall survival; PFS,
progression‐free survival [Color figure can be viewed at
wileyonlinelibrary.com]
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(n = 1), gastrointestinal bleeding (n = 1), and ascites (n = 1). All serious
adverse events of the FOLFIRINOX treatment are summarized in
Table 2. No deaths were attributed to FOLFIRINOX. Only one (6%)
patient had a serious adverse event of grade 3 of diarrhea during RT.
Three (14%) patients underwent an exploratory laparotomy after
FOLFIRINOX and RT. One (5%) patient was found to have peritoneal
metastasis at exploratory laparotomy and underwent a gastric
bypass. Two (9%) patients underwent a curative‐intent resection;
modified Appleby resection, and one a distal pancreatectomy. Both
(100%) resections were radical (R0, closest margin >1mm). Survival
time after resection was 16 and 10 months in two patients with a
partial response in histopathological examination.
4 | DISCUSSION
In this cohort study, 22 patients with LAPC received FOLFIRINOX
with subsequent conventional RT. The median OS was 15 months
and the PFS 11 months. Most patients (77%) completed both
chemotherapy and RT. No mortality was attributed to the treatment,
but 64% had at least one grade 3 or 4 toxicity. Nineteen patients with
LAPC did not receive the protocolled care for various reasons
resulting in a median OS of 6.2 months.
Since the randomized controlled trial conducted by Conroy et al5
showed a survival benefit for FOLFIRINOX vs gemcitabine for
metastatic pancreatic cancer, many case series were published that
evaluated the survival effect of FOLFIRINOX for patients with
LAPC.9-20 However, no randomized controlled trials have been
published that confirm the survival benefit of FOLFIRINOX in LAPC
patients. A recent patient‐level meta‐analysis of 315 LAPC patients
treated with first‐line FOLFIRINOX showed a median OS of
24.2 months and PFS of 15 months.6
Our median OS and PFS is lower than found in the meta‐analysis.
However, most studies in the meta‐analysis were retrospective,
which may cause selection bias. On the other hand, we used a staging
laparoscopy before the treatment to rule out the occult metastatic
disease. This approach is based upon two studies that have shown
that 34% and 35% of patients with LAPC are found to have clinically
and radiographically‐undetermined metastatic disease during staging
laparoscopy.21,22
The FOLFIRINOX treatment toxicity of 59% serious adverse
events is comparable to the other studies published about this
treatment regimen, with the meta‐analysis showing a 60% of serious
adverse events during the treatment. Despite this high toxicity
profile, FOLFIRINOX showed a better quality of life than gemcitabine
in the PRODIGE 4 trial, probably by deferring definitive
deterioration.23
RT had a very low rate of serious adverse events (6%) in our
study and therefore is safe to give as the subsequent treatment after
the first‐line FOLFIRNOX. However, whether conventional RT
improves survival for LAPC patients has not been evaluated in a
randomized controlled trial.4 In regard of chemoradiotherapy, in
2016 Hammel et al24 published the LAP07 randomized controlled
trial which randomized patients with LAPC for induction chemother-
apy (gemcitabine vs gemcitabine and erlotinib), followed by a second
randomization of continuing chemotherapy vs chemoradiotherapy
(54 Gy plus capecitabine). During the interim analysis, the study was
stopped as it reached the early stopping boundaries for futility.
However, the study did not show a significant median OS benefit
between continuing chemotherapy or subsequent chemoradiother-
apy after induction chemotherapy with a median survival of 16.5 vs
15.2 months, respectively. The major disadvantage of conventional
fractionated RT for pancreatic cancer is that although the pancreas is
relatively radioresistant, the surrounding organs are highly radio-
sensitive.25 In the last years, stereotactic body RT (SBRT) has
emerged as the preferred RT after the systemic chemotherapy for
LAPC. SBRT allows for a higher dose of RT to the pancreatic tumor
with less radiation to the surrounding organs.26 A low rate of serious
adverse events (7%) was also seen by Mellon et al27 when SBRT was
given as therapy for borderline resectable and locally advanced
pancreatic cancer after induction chemotherapy.
In our study, two patients (9%) underwent a resection with, both
being a radical resection. This rate was lower than the pooled
resection rate of 28% as shown in the meta‐analysis.6 In our clinic,
the decision to do an exploration after induction therapy is based on
the same definitions for LAPC. So arterial tumor encasement should
not exceed 90 degrees and venous encasement should not exceed
270 degrees. These more conservative criteria for exploration could
have led to a lower resection rate than given in other studies.
Furthermore, the meta‐analysis did not detect an association
between a studied resection rate and survival. Some studies report
remarkable survival outcomes in LAPC patients after induction
FOLFIRINOX and resection. However, these patients are highly
selective and the favorable outcomes may be largely attributable to
guaranteed‐time bias.28,29 The most recent American Society of
Clinical Oncology guideline advises that all patients with LAPC
should receive first‐line chemotherapy with or without RT, and
surgery should be only considered if a dramatic response to induction
TABLE 2 Serious adverse events during FOLFIRINOX, n = 13
Description Grade 3 Grade 4
Diarrhea 4 0
Elevated ALT/AST 1 2
Neutropenic fever 1 0
Ascites 1 0
Fatigue 1 0
GI bleeding 0 1
Mucositis 1 0
Nausea 1 0
Paresthesia 0 0
Total 10 3
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase;
GI, gastrointestinal.
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therapy was achieved.4 In our clinic, the decision to do an exploration
after induction therapy is based on the same definitions for LAPC. So
arterial tumor encasement should not exceed 90 degrees and venous
encasement should not exceed 270 degrees. These more conserva-
tive criteria for exploration could have led to a lower resection rate
than given in other studies. Future studies should determine which
patients could potentially benefit from a resection after induction
chemotherapy.
Our study has several limitations. The main limitation is that the
sample size of patients who received the full treatment is small to
draw definitive conclusions. However, despite the small sample size,
this study gives an overview of how many patients eventually receive
induction chemotherapy after the diagnosis of LAPC. Furthermore,
there is no general consensus in the definition for LAPC that can help
generalize the interpretation of different treatment regimens.
Although the Dutch Pancreatic Cancer Group definitions for LAPC
are more conservative than the most commonly used definitions such
as NCCN and AHPBA/SSO/SSAT definitions,30,31 there is no
evidence that there is a difference in survival because of these
criteria. In addition, conventional RT was used in this study while
SBRT can maybe induce a better local control as mentioned above.
In conclusion, this study gives an overview of the current practice
and strategy of patients with LAPC in the Netherlands. FOLFIRINOX
followed by RT can be offered to a limited number of patients, but it
could be considered safe and shows promising survival results for
patients with LAPC. Randomized controlled trials are needed to
determine the value of RT, and resection in addition to FOLFIRINOX
in patients with LAPC.
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